Osiris Therapeutics (OSIR) 5.01 $OSIR Osiris Provides

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 11:01 AM

Osiris Therapeutics (OSIR) 5.01 $OSIR

Osiris Provides Update Regarding NASDAQ Listing Matters
GlobeNewswire - Wed Aug 17, 4:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the "Company"

today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market ("NASDAQ"

.
OSIR: 5.01 (unch)

Osiris Therapeutics, Inc. (Nasdaq: OSIR) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Fri Aug 05, 9:00AM CDT
What:
OSIR: 5.01 (unch), NDAQ: 71.24 (+0.03)

Grafix(R) Manuscript Reporting Positive Outcomes of Multicenter Chronic Complex Wounds with Exposed Tendon and Bone Clinical Trial is Available Electronically in Peer-Reviewed Journal
GlobeNewswire - Thu Aug 04, 3:33PM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that the manuscript from its multicenter prospective post-market clinical trial using Grafix was accepted for publication in the International Wound Journal, is now available online and will appear in an upcoming issue of the journal.
OSIR: 5.01 (unch)

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Claims against Osiris Therapeutics, Inc. and Advises Investors to Contact the Firm
BusinessWire - Thu Jun 02, 11:49AM CDT
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Osiris Therapeutics, Inc. ("Osiris" or the "Company"

(Nasdaq: OSIR). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
OSIR: 5.01 (unch)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Osiris Therapeutics, Inc. -- OSIR
BusinessWire - Wed Jun 01, 10:08AM CDT
Levi & Korsinsky announces it has commenced an investigation of Osiris Therapeutics, Inc. ("Osiris Therapeutics" or the "Company"

(NASDAQ: OSIR) concerning possible violations of federal securities laws.
OSIR: 5.01 (unch), MDXG: 7.08 (-0.16)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Osiris Therapeutics, Inc.
PR Newswire - Wed Jun 01, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Osiris Therapeutics, Inc. ("Osiris" or the "Company"

(NasdaqGM: OSIR -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at
OSIR: 5.01 (unch)

INVESTOR ALERT: Investigation of Osiris Therapeutics, Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Tue May 31, 1:28PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Osiris Therapeutics, Inc. ("Osiris" or the "Company"

(NASDAQ: OSIR) concerning the Company and its officers' possible violations of federal securities laws.
OSIR: 5.01 (unch)

MiMedx Files Lawsuit Against Osiris For False And Misleading Representations
PR Newswire - Tue May 17, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it has filed a lawsuit under the Lanham Act against Osiris Therapeutics, Inc. for permanent injunctive relief and damages.
OSIR: 5.01 (unch), MDXG: 7.08 (-0.16)

Osiris to Present at the 26th European Wound Management Association Conference
BusinessWire - Tue May 10, 3:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present advanced clinical and scientific research at the 26th European Wound Management Association Conference.
OSIR: 5.01 (unch), SYK: 114.94 (-0.72)

Grafix Demonstrates Superior Clinical Outcomes Compared with EpiFix in "Real World" Study
BusinessWire - Mon May 02, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company, focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announces the results of A Retrospective, Single-Center, Non-Randomized, Cross-Sectional Comparative Effectiveness Study Evaluating Surface Area Reduction, Volume Reduction and Closure Rates in Acute and Chronic Wounds Managed with Grafix(R) versus EpiFix(R).
OSIR: 5.01 (unch), SYK: 114.94 (-0.72)

Osiris to Present 15 Advanced Clinical and Scientific Abstracts
BusinessWire - Tue Apr 12, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present advanced clinical and scientific research at the Symposium on Advanced Wound Care (SAWC) and Wound Healing Society Spring Conference, the nation's largest interdisciplinary wound care event within the clinical field.
OSIR: 5.01 (unch), SYK: 114.94 (-0.72)

Osiris Announces Further Expansion of Grafix Commercial Coverage
BusinessWire - Fri Apr 08, 11:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that over 52 million commercial beneficiaries are covered for Grafix(R).
OSIR: 5.01 (unch), SYK: 114.94 (-0.72)

Dipexium Progresses on Phase III Diabetic Foot Ulcer Studies
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 2:50PM CST
Dipexium (DPRX) attains 75% enrollment milestone in two phase III studies on Locilex for the treatment of patients with mild infections of diabetic foot ulcers.
DPRX: 12.58 (-0.12), OSIR: 5.01 (unch), LGND: 104.53 (+1.22), ANIK: 46.80 (-0.44)

Shares of OSIR Down 63.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Feb 04, 3:37PM CST
SmarTrend identified a Downtrend for Osiris Therapeutics (NASDAQ:OSIR) on October 6th, 2015 at $16.79. In approximately 4 months, Osiris Therapeutics has returned 63.06% as of today's recent price of $6.20.
OSIR: 5.01 (unch)

Why Shares of Osiris Therapeutics Tanked Today
George Budwell, The Motley Fool - Motley Fool - Thu Feb 04, 10:15AM CST
What : Shares of the regenerative-medicine company Osiris Therapeutics fell by as much as 16% in early trading Thursday on modest volume after the company announced a major shake-up in its leadership team. Specifically, Dwayne Montgomery is taking...
OSIR: 5.01 (unch)

Osiris Therapeutics Announces Leadership Transition
BusinessWire - Wed Feb 03, 3:30PM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Dwayne Montgomery, its current Chief Business Officer, has been appointed today to serve as Interim Chief Executive Officer. Frank Czworka, currently Vice President and General Manager of Wound Care, has been promoted to Chief Operating Officer. Mr. Montgomery will replace Dr. Lode Debrabandere who today has announced his resignation for personal reasons from Osiris.
OSIR: 5.01 (unch), SYK: 114.94 (-0.72)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Geron Corp Faces Fiduciary Duty Investigation

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

CVS Health Under Fire: Fiduciary Duty Breach?

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Timur Turlov Leads FIDE with Chess and Digital Focus

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

HONA Faces Legal Heat: Investor Lawsuit Over Losses

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Quay Sunglasses: Luxury Looks, Affordable Prices

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...